Scholarlink

<p>Mefenamic acid plays an important role in relieving pain and treating mild to moderate infections. It is classified as a nonselective nonsteroidal anti-inflammatory drug (nsNSAID) that prevents the formation of prostaglandins from arachidonic acid by inhibiting cyclooxygenase enzymes (COXs). Three new mefenamic acid-based derivatives were prepared as tertiary drug systems. Initially, mefenamic acid was reacted with EDC.HCl and NHS, followed by 5-aminosalicylic acid, to produce the compound AY1 as a binary drug system. AY1 was then used as a starting material to produce tertiary pharmaceutical compounds by reacting it with three different amino drugs, yielding new compounds: AY2, AY3, and AY4 with yields greater than 70%. All the prepared compounds were characterized via FT-IR, 1H-NMR, 13C-NMR, and CHNS. AY2, AY3, and AY4 were tested for their anticancer activity against breast cancer cells, with AY4 showing the lowest IC<sub>50</sub> value of 14.94 µg/mL. The antibacterial activity of all the prepared compounds was also studied against <i>E. coli</i> and <i>S. aureus</i>, with AY4 exhibiting the largest inhibition zone (38 and 32 mm). The solubility of the synthesized compounds in various solvents was also investigated.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluation of the anticancer and antibacterial activities of several new drug conjugated systems based on mefenamic acid

  • 期刊论文

  • 发表日期：

    2026年7月22日

查看全文
  • Ayad A. Disher,
  • Mohanad Mousa Kareem,
  • Ammar Abdul Hussein Awad

摘要

Mefenamic acid plays an important role in relieving pain and treating mild to moderate infections. It is classified as a nonselective nonsteroidal anti-inflammatory drug (nsNSAID) that prevents the formation of prostaglandins from arachidonic acid by inhibiting cyclooxygenase enzymes (COXs). Three new mefenamic acid-based derivatives were prepared as tertiary drug systems. Initially, mefenamic acid was reacted with EDC.HCl and NHS, followed by 5-aminosalicylic acid, to produce the compound AY1 as a binary drug system. AY1 was then used as a starting material to produce tertiary pharmaceutical compounds by reacting it with three different amino drugs, yielding new compounds: AY2, AY3, and AY4 with yields greater than 70%. All the prepared compounds were characterized via FT-IR, 1H-NMR, 13C-NMR, and CHNS. AY2, AY3, and AY4 were tested for their anticancer activity against breast cancer cells, with AY4 showing the lowest IC50 value of 14.94 µg/mL. The antibacterial activity of all the prepared compounds was also studied against E. coli and S. aureus, with AY4 exhibiting the largest inhibition zone (38 and 32 mm). The solubility of the synthesized compounds in various solvents was also investigated.

Graphical abstract